Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS1 | P23219 | 7/20 | 0.72 |
| ▸ | PTGS2 | P35354 | 7/20 | 0.72 |
| ▸ | MGLL | Q99685 | 8/20 | 0.68 |
| ▸ | FAAH | O00519 | 5/20 | 0.68 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.68 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.68 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.68 |
| ▸ | LMNA | P02545 | 1/20 | 0.68 |
| ▸ | TP53 | P04637 | 1/20 | 0.68 |
| ▸ | MAPT | P10636 | 1/20 | 0.68 |
| ▸ | PKM | P14618 | 1/20 | 0.68 |
| ▸ | HPGD | P15428 | 1/20 | 0.68 |
| ▸ | XBP1 | P17861 | 1/20 | 0.68 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.68 |
| ▸ | HTT | P42858 | 1/20 | 0.68 |
| ▸ | RECQL | P46063 | 1/20 | 0.68 |
| ▸ | RAB9A | P51151 | 1/20 | 0.68 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.68 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.68 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.68 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19817136 | 1.00 | PTGS1 (0.72) | PTGS1PTGS2MGLLFAAHHSP90AA1 | |
| SCHEMBL28698933 | 1.00 | PTGS1 (0.72) | PTGS1PTGS2MGLLFAAHHSP90AA1 | |
| SCHEMBL30180925 | 1.00 | PTGS1 (0.72) | PTGS1PTGS2MGLLFAAHHSP90AA1 | |
| SCHEMBL22398888 | 0.98 | PTGS1 (0.69) | PTGS1PTGS2MGLLFAAHHSP90AA1 | |
| Acetic Acid SCHEMBL27987918 | 0.93 | PTGS1 (0.69) | PTGS1PTGS2MGLLFAAHHSP90AA1 | |
| SCHEMBL1704532 | 0.92 | MGLL (0.62) | PTGS1PTGS2MGLLFAAHHSP90AA1 | |
| Trifluoroacetic Acid SCHEMBL30433783 | 0.88 | PTGS1 (0.63) | PTGS1PTGS2MGLLFAAHHSP90AA1 | |
| SCHEMBL23506702 | 0.88 | PTGS1 (0.57) | PTGS1PTGS2MGLLFAAHHSP90AA1 | |
| Urea SCHEMBL29007233 | 0.87 | PTGS1 (0.89) | PTGS1PTGS2MGLLFAAHHSP90AA1 | |
| SCHEMBL3962821 | 0.86 | PTGS1 (0.55) | PTGS1PTGS2MGLLFAAHHSP90AA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 133 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4729525-A1 | NEWLY SYNTHESIZED BORON-NITROGEN HETEROCYCLES AND THEIR CONJUGATES WITH PHARMACEUTICALLY UTILIZABLE SUBSTANCES | Julius-Maximilians-Universität Würzburg (DE) | 2026-04-22 | — | — | EP | claimed |
| US-20240066138-A1 | ANTIBODY-DRUG CONJUGATES, PHARMACEUTICAL COMPOSITIONS, AND THERAPEUTIC APPLICATIONS | SHANGHAI RUOTUO BIOSCIENCES CO LTD (CN) | 2024-02-29 | — | — | US | claimed |
| EP-1294707-A2 | THIOPHENE DERIVATIVES ACTIVE AS KINASE INHIBITORS, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS COMPRISING THEM | Pharmacia Italia S.p.A. (IT) | 2003-03-26 | — | — | EP | claimed |
| WO-2001098290-A2 | THIOPHENE DERIVATIVES ACTIVE AS KINASE INHIBITORS, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS COMPRISING THEM | PHARMACIA ITALIA S.P.A. (IT) | 2001-12-27 | — | — | WO | claimed |
| EP-4729525-A1 | NEWLY SYNTHESIZED BORON-NITROGEN HETEROCYCLES AND THEIR CONJUGATES WITH PHARMACEUTICALLY UTILIZABLE SUBSTANCES | Julius-Maximilians-Universität Würzburg (DE) | 2026-04-22 | — | — | EP | disclosed |
| EP-4725560-A2 | ANTI-B7H3 ANTIBODIES FOR THE PREPARATION OF ANTIBODY DRUG CONJUGATES (ADCS) OF KSP INHIBITORS | Bayer Pharma Aktiengesellschaft (DE) | 2026-04-15 | — | — | EP | disclosed |
| EP-3868384-B1 | CYCLIC DINUCLEOTIDES AS STING (STIMULATOR OF INTERFERON GENES) AGONISTS | TAKEDA PHARMACEUTICALS CO (JP) | 2026-02-25 | — | — | EP | disclosed |
| EP-4696331-A1 | ANTI-CDH6 ANTIBODY-DRUG CONJUGATE AND USE THEREOF | Hainan Simcere Zaiming Pharmaceutical Co., Ltd. (CN) | 2026-02-18 | — | — | EP | disclosed |
| EP-4673474-A2 | ANTI-PSMA ANTIBODIES, CONJUGATES, AND METHODS OF USE | Eisai R&D Management Co., Ltd. (JP) | 2026-01-07 | — | — | EP | disclosed |
| US-12514928-B2 | Herboxidiene antibody-drug conjugates and methods of use | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2026-01-06 | — | — | US | disclosed |
| US-12514926-B2 | Splicing modulator antibody-drug conjugates and methods of use | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2026-01-06 | — | — | US | disclosed |
| US-20260000777-A1 | NECTIN-4 ANTIBODY CONJUGATES AND USES THEREOF | ARARIS BIOTECH AG (CH) | 2026-01-01 | — | — | US | disclosed |
| WO-2005016960-A2 | AMINO ACID SEQUENCES FACILITATING PENETRATION OF A SUBSTANCE OF INTEREST INTO CELLS AND/OR CELL NUCLEI | DIATOS (FR) | 2005-02-24 | — | — | WO | disclosed |
| US-20040242854-A1 | Chemical capture reagent | GE HEALTHCARE UK LIMITED (GB) | 2004-12-02 | — | — | US | disclosed |
| EP-1402268-A2 | CHEMICAL CAPTURE REAGENT | Amersham Biosciences UK Limited (GB) | 2004-03-31 | — | — | EP | disclosed |
| WO-2003005026-A2 | CHEMICAL CAPTURE REAGENT | AMERSHAM BIOSCIENCES UK LIMITED (GB) | 2003-01-16 | — | — | WO | disclosed |
| US-6414013-B1 | KINASE INHIBITORS; ANTICANCER AGENTS | PHARMACIA & UPJOHN S.P.A. (IT) | 2002-07-02 | — | — | US | disclosed |
| US-4954638-A | ANTIALLERGENS, ANTIINFLAMMATORY | MERCK FROSST CANADA, INC. (CA) | 1990-09-04 | — | — | US | disclosed |
| US-4767745-A | 1,5-DIFLUORO-2,4-DINITRO BENZENE AND 6-N-MALEIMIDOHEXANOIC ACID CHLORIDE AS COUPLING AGENTS; ANTIALLERGENS, ANTIINFLAMMATORY AGENTS | MERCK FROSST CANADA, INC. (CA) | 1988-08-30 | — | — | US | disclosed |
| EP-0179959-A1 | Conjugates of leukotrienes with proteins | MERCK FROSST CANADA INC. (CA) | 1986-05-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260000777-A1 | NECTIN-4 ANTIBODY CONJUGATES AND USES THEREOF | NECTIN4, IGSF11, VSIG8 | PTGS1 4327/4885PTGS2 4547/4885MGLL 4137/4885 |
| US-20240066138-A1 | ANTIBODY-DRUG CONJUGATES, PHARMACEUTICAL COMPOSITIONS, AND THERAPEUTIC APPLICATIONS | FCGR1A, FCGRT, FCGR2A | PTGS1 3081/4885PTGS2 3832/4885MGLL 4442/4885 |
| US-20040242854-A1 | Chemical capture reagent | SPPL2B, PRXL2A, PLG | PTGS1 1219/4885PTGS2 2425/4885MGLL 2343/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.